Continuity of Care and Functional Outcomes in Schizophrenia

ReachMD Healthcare Image

Treating adults with schizophrenia involves more than acute symptom control. To promote the continuity of care, clinicians also need to consider transitions after hospitalization and practical ways to support patients who may have difficulty adhering to a daily regimen.

Now, healthcare providers have a new way to help adult patients with schizophrenia start and stay on treatment. WELTRUZA™ (olanzapine) extended-release injectable suspension is the only FDA-approved subcutaneous formulation of olanzapine administered once monthly by a healthcare professional.1 In the clinical study, its safety profile was similar to that of oral olanzapine.1,2

The following overview details why long-acting treatment may be relevant for some patients, how WELTRUZA was studied in the SOLARIS phase 3 clinical trial, and what was demonstrated across symptoms, functioning, dosing, administration, and safety.

Section 1: Adherence remains a challenge for patients

Long-term treatment adherence remains a challenge for many adults with schizophrenia. In a retrospective analysis of US insurance claims, 67% of patients who managed their schizophrenia with pills were nonadherent or discontinued treatment within 12 months of initiation.3 Nonadherence to antipsychotics can make it more difficult to sustain long-term symptom control, increasing illness severity and the risk of relapse.4

The transition of care after hospitalization can be a critical point in the treatment journey. Adherence to treatment post-discharge can help prevent worsening of symptoms and disease progression.5 Yet, almost 73% of patients discontinue antipsychotic medication 30 days post-hospitalization.6

Many people living with schizophrenia have goals that extend beyond symptom reduction, including stable housing, strong relationships, career success, fulfillment, optimism, and stability.7 While WELTRUZA has not been studied for treatment adherence outcomes or for its impact on these broader life goals, they are important within the context of long-term treatment continuity in schizophrenia care.

“Hospital treatment decisions can help shape continuity of care in outpatient and institutional care settings.”6

Section 2: How WELTRUZA was studied in SOLARIS

The SOLARIS clinical trial for WELTRUZA evaluated the efficacy, safety, and tolerability of once-monthly WELTRUZA in adults with schizophrenia experiencing acute symptoms. The pivotal clinical trial was a phase 3, randomized, double-blind, placebo-controlled study with a 48-week, open-label safety phase. In the acute treatment phase, 675 participants were randomized into 3 dosing groups (318 mg, 425 mg, 531 mg) and a placebo group; in the long-term safety phase, 423 participants were rerandomized into the above 3 dosing groups.2

The primary endpoint was change from baseline in Positive and Negative Syndrome Scale (PANSS) total score at week 8 versus placebo. Key secondary endpoints were change from baseline at week 8 in Clinical Global Impression—Severity (CGI-S) and Personal and Social Performance (PSP) scores. CGI-S is a clinician-rated 7-point scale that evaluates overall illness severity, with lower scores indicating improvement. PSP is a clinician-rated 100-point scale that evaluates personal and social functioning, with higher scores indicating better functioning. The PSP assessment includes domains that may be meaningful to everyday life: socially useful activities such as work and study, personal and social relationships, self-care, and disturbing or aggressive behaviors. Together, these measures help characterize the impact of WELTRUZA not only on schizophrenia symptoms but also on illness severity and personal and social functioning.1

The study population included patients with schizophrenia experiencing acute exacerbations requiring hospitalization. In the total WELTRUZA group, median age was 45 years, 75% were male, median disease length was 18.7 years, 24% had prior use of olanzapine, and the mean PANSS score was 95.8.1,2

PANSS total score at week 8 and through the open-label safety phase in the SOLARIS trial

Section 3: What the clinical data showed

In the 8-week, randomized, double-blind, placebo-controlled acute treatment phase in adults with acute schizophrenia exacerbation, WELTRUZA met the primary endpoint of change from baseline in PANSS total score at week 8 versus placebo.8 PANSS total score is a clinician-rated measure used to assess schizophrenia symptoms. In SOLARIS, WELTRUZA significantly reduced total PANSS scores across all 3 doses by week 8.8 The least squares (LS) mean changes from baseline to week 8 were -21.91, -23.44, and -21.93 for WELTRUZA 318 mg, 425 mg, and 531 mg, respectively, versus -12.17 for placebo.1 Across doses, WELTRUZA was associated with a 22.4-point reduction in PANSS total score versus 12.17 with placebo (P<.0001).1

Section 4: Looking beyond symptom improvement

The data also looked beyond the primary endpoint symptom scores. Illness severity was evaluated with CGI-S, a clinician-rated 7-point scale in which lower scores indicate improvement. By week 8, CGI-S scores were reduced by 1.25, 1.33, and 1.19 points from baseline for WELTRUZA 318 mg, 425 mg, and 531 mg, compared with 0.72 points for placebo.1,2 LS mean differences versus placebo were -0.53, -0.61, and -0.47 for the 318 mg, 425 mg, and 531 mg doses (P<.0001).2,8 These data also show an approximately 26% reduction in illness severity from baseline compared with 15% for placebo.2 

Personal and social functioning was evaluated with PSP, a clinician-rated 100-point scale in which higher scores indicate better functioning. The PSP scale evaluates personal and social functioning across socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behaviors.1 By week 8, PSP total scores improved by 10.31, 8.83, and 10.59 points from baseline for WELTRUZA 318 mg, 425 mg, and 531 mg, respectively, compared with 5.59 points for placebo.2 LS mean differences versus placebo were 4.72, 3.24, and 5.01 for the 318 mg, 425 mg, and 531 mg doses, respectively (P<.02).2,8 These data also show an approximately 20% improvement in personal and social functioning from baseline compared with 11% for placebo.2

In the open-label safety period, patients treated with WELTRUZA demonstrated sustained improvements in PANSS, CGI-S, and PSP scores through 48 weeks of treatment.1 The PANSS score change from open-label safety extension baseline to end of study was -7.2 points.2

Safety findings from SOLARIS should be considered alongside efficacy and functioning data. Discontinuations due to common adverse events (AEs) were 5% for WELTRUZA and 4% for placebo.1 The most common AEs (≥5%) were weight gain, somnolence, headache, constipation, and injection site reactions (induration, pain, erythema, pruritus, swelling).1 Serious AEs were reported in 1% of patients treated with WELTRUZA.2 Weight gain and metabolic changes were observed and were consistent with the known safety profile of olanzapine, including clinically significant weight gain (≥7% of baseline body weight).1 Most injection site reactions were generally localized and occurred early in treatment. They were self-limiting, declining over the long-term from the first (24%) to the 8th (2%) injection and onwards.1,2

“Patients treated with WELTRUZA saw a reduction in illness severity and improvements
in personal and social functioning.”1

Section 5: The significance of daily functioning data

For many adults with schizophrenia, the clinical conversation may extend beyond symptom control. PANSS establishes symptom improvement, while CGI-S and PSP help clinicians understand how treatment response appears in overall illness severity and functioning. This distinction is important because personal and social functioning is measured through domains that connect more directly to everyday life, including socially useful activities such as work and study, personal and social relationships, self-care, and disturbing or aggressive behaviors.1

Together, the PANSS, CGI-S, and PSP results provide a more comprehensive picture of treatment response. 

Section 6: Appropriate patient considerations and support resources

WELTRUZA may be considered for adults with schizophrenia who are currently prescribed oral olanzapine and looking for a long-acting treatment, have previously tolerated olanzapine, and/or have difficulty maintaining a daily regimen.1,4 A representative patient profile may include an adult currently treated with oral olanzapine who frequently misses daily doses, was recently hospitalized due to worsening positive symptoms, and may benefit from a long-acting option that does not require a daily dose.

Teva Total Support™ is designed to help patients start and stay on the treatment prescribed by their HCP. The program can help with benefits investigations, prior authorization navigation, specialty pharmacy coordination, financial assistance options, personalized services, and one-on-one nurse support.
Download the Prescription and Service Request Form to request Teva Total Support services for appropriate patients.

Consider a Different Form of Olanzapine for the Long-Term Treatment Journey

WELTRUZA offers clinicians a different form of olanzapine for adults with schizophrenia: a once-monthly, subcutaneous long-acting injectable with demonstrated improvement in symptoms and personal and social functioning at week 8 versus placebo.1,2 It requires no loading dose and no oral supplementation.1 In SOLARIS, the overall safety profile of WELTRUZA was similar to that of oral olanzapine.1,2 For appropriate adults who have tolerated olanzapine, including those transitioning from oral olanzapine, WELTRUZA may be a treatment option to consider as part of long-term schizophrenia care planning.1

Explore WELTRUZA dosing and administration information.

Completing the pre-test is required to access this content.
Pre-Survey
Completing the pre-survey is required to access this content.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free